|
Ms Chu joined EDB Investments Pte Ltd (EDBI) as its Chief Executive Officer in late 2008, bringing with her over 20 years of track record and extensive experience in equity investments of start-up to growth and late-stage ventures, strategic planning, business and technology development.
Ms Chu was the CEO of EDBI subsidiary, Bio*One Capital Pte Ltd, since 2004. Under her leadership, the team made many impactful investments which helped transformed the Singapore biomedical industry. Bio*One is now a globally recognised investment fund manager with a portfolio of over 50 therapeutics, medical technology and services companies worldwide and in Singapore.
Previously Ms Chu held major stints at the SEDB and Agency for Science & Technology Research (A*STAR) where she played a pioneering role in developing and implementing key strategies leading to the growth of the biomedical industry as a major pillar of Singapore's economy today. She was instrumental in establishing several early venture funds in SEDB including setting its policies and management. Ms Chu was also responsible for many successful negotiations with global MNCs relating to their R&D, manufacturing and headquarters activities in Singapore.
Besides the board of EDBI, Ms Chu also serves on the boards of Novartis Institute for Tropical Diseases (NITD), Merlion Pharmaceuticals Pte Ltd, S*Bio Pte Ltd, Xinya Media Pte Ltd, Singapore-Suzhou Township Development Pte Ltd, and Alexandra Health Endowment Fund.
|